-
Product Insights
Rigel (Prosper Petroleum Ltd.) Upstream Project , Canada
Rigel (Prosper Petroleum Ltd.) upstream project is located in Alberta, Canada. The upstream project is owned by Lama Energy Group Sro (39.30%); Prosper Petroleum Ltd (60.70%). It will be operated by Prosper Petroleum Ltd. The project is currently in the announced stage and is expected to start operations in 2023. Rigel (Prosper Petroleum Ltd.) Upstream profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well...
-
Company Profile
![]()
Rigel Pharmaceuticals Inc – Company Profile
Rigel Pharmaceuticals Inc (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer, and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. The company’s lead product, the US FDA approved Tavalisse (fostamatinib disodium hexahydrate), is an oral spleen tyrosine kinase inhibitor to treat adult patients with chronic immune thrombocytopenia, and Rezlidhia (olutasidenib) for the treatment of adult patients with R/R AML with a...
Add to Basket -
Product Insights
Flyndre Field, United Kingdom
Flyndre upstream field is located in North Sea, Norway. The upstream field is owned by Petrolia NOCO AS (0.82%); Rigel Petroleum (NI) Ltd (92.92%); TotalEnergies EP Norge AS (6.26%). It is operated by Rigel Petroleum (NI) Ltd. The project started its operations in 2017. Flyndre Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and...
-
Product Insights
Scapa Field, United Kingdom
Scapa upstream field is located in North Sea, United Kingdom. The upstream field is owned by Repsol Sinopec Delta Ltd (99%); Repsol Sinopec Resources UK Ltd (0%); Rigel Petroleum (NI) Ltd (1%). It is operated by Repsol Sinopec Resources UK Ltd. The project started its operations in 1984. Scapa Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data...
-
Product Insights
Blake Field, United Kingdom
Blake upstream field is located in North Sea, United Kingdom. The upstream field is owned by Repsol Sinopec North Sea Ltd (2.40%); Repsol Sinopec Resources UK Ltd (33.60%); Rigel Petroleum UK Ltd (33.18%); Rockrose UKCS4 Ltd (30.82%). It is operated by Repsol Sinopec Resources UK Ltd. The project started its operations in 2001. Blake Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NN-6581 in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NN-6581 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:NN-6581 is under development for the treatment of non-alcoholic steatohepatitis (NASH)....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Forimtamig in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Forimtamig in Refractory Multiple MyelomaDrug Details: Forimtamig (RO-7425781) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – R-835 in Rheumatoid Arthritis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. R-835 in Rheumatoid Arthritis Drug Details: R-835 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – R-289 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.R-289 in Myelodysplastic Syndrome Drug Details:R-289 is under development for myelodysplastic syndrome and immune diseases such...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MTX-071 in Osteoarthritis Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MTX-071 in Osteoarthritis Pain Drug Details:MTX-071 (Lopain) is under development for the treatment of chronic osteoarthritic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – R-289 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.R-289 in InflammationDrug Details:R-289 is under development for myelodysplastic syndrome and immune diseases such as inflammation....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rademikibart in Asthma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rademikibart in Asthma Drug Details: CBP-201 is under development for the treatment of allergic inflammation...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NMS-293 in Oligodendroglioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NMS-293 in OligodendrogliomaDrug Details:NMS-293 is under development for the treatment of recurrent glioblastoma multiforme (GBM), diffuse...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07284892 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PF-07284892 in Solid Tumor Drug Details:PF-07284892 is under development for the treatment of ALK- or ROS1-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – React in Chronic Kidney Disease (Chronic Renal Failure)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.REACT in Chronic Kidney Disease (Chronic Renal Failure) Drug Details:REACT is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LEU-001 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LEU-001 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Drug Details:LEU-001 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Filgotinib Maleate in Axial Spondyloarthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Filgotinib Maleate in Axial Spondyloarthritis Drug Details: Filgotinib maleate (Jyseleca) acts as an antirheumatic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Chondrosarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Olutasidenib in ChondrosarcomaDrug Details:Olutasidenib (Rezlidhia) is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is formulated as hard...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Hepatobiliary System Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Olutasidenib in Hepatobiliary System TumorDrug Details:Olutasidenib (Rezlidhia) is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Bile Duct Cancer (Cholangiocarcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Olutasidenib in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:Olutasidenib (Rezlidhia) is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.